Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 23

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 23
---
 Leerink Partners LLC are the representatives of the underwriters.

| Underwriters            |     | Number of Shares |
| Goldman Sachs & Co. LLC |     |        6,136,364 |
| Leerink Partners LLC    |     |        4,772,727 |
| Evercore Group L.L.C.   |     |        2,727,273 |
| Total                   |     |       13,636,364 |

The underwriters are committed to take and pay for all of the shares being offered, if any are taken. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by the company.

| Paid by the Company |     |   |              |
|:--------------------|:----|:--|-------------:|
| Per Share           |     | $ |       0.5775 |
| Total               |     | $ | 7,875,000.21 |

Shares sold by the underwriters to the public will initially be offered at the offering price set forth on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $0.3465 per share from the offering price set forth on the cover of this prospectus. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part. The company has agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of its common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus supplement continuing through the date 60 days after the date of this prospectus supplement, except with the prior written consent of the representatives. These restrictions do not apply to: (i) the issuance of shares in this offering; (ii) the issuance of common stock or any securities convertible into, or exercisable for, shares of common stock pursuant to our equity incentive plans and employee stock purchase plan and such other plans and arrangements as are in existence on the date of this prospectus; (iii) the issuance of common stock pursuant to the valid exercises, vesting or settlements of options, other equity awards, warrants or rights outstanding on the date of this prospectus; (iv) the filing of a registration statement on Form S-